PubMed Health⌕ Search

PubMed · 12870898

Toward generating simpler QSAR models: nonlinear multivariate regression versus several neural network ensembles and some related methods.

Abstract

In this study we want to test whether a simple modeling procedure used in the field of QSAR/QSPR can produce simple models that will be, at the same time, as accurate as robust Neural Network Ensemble (NNE) ones. We present results of application of two procedures for generating/selecting simple linear and nonlinear multiregression (MR) models: (1) method for selecting the best possible MR models (named as CROMRsel) and (2) Genetic Function Approximation (GFA) method from the Cerius2 program package. The obtained MR models are strictly compared with several NNE models. For the comparison we selected four QSAR data sets previously studied by NNE (Tetko et al. J. Chem. Inf. Comput. Sci. 1996, 36, 794-803. Kovalishyn et al. J. Chem. Inf. Comput. Sci. 1998, 38, 651-659.): (1) 51 benzodiazepine derivatives, (2) 37 carboquinone derivatives, (3) 74 pyrimidines, and (4) 31 antimycin analogues. These data sets were parameterized with 7, 6, 27, and 53 descriptors, respectively. Modeled properties were anti-pentylenetetrazole activity, antileukemic activity, inhibition constants to dihydrofolate reductase from MB1428 E. coli, and antifilarial activity, respectively. Nonlinearities were introduced into the MR models through 2-fold and/or 3-fold cross-products of initial (linear) descriptors. Then, using the CROMRsel and GFA programs (J. Chem. Inf. Comput. Sci. 1999, 39, 121-132) the sets of I (I < or = 8, in this paper) the best descriptors (according to the fit and leave-one-out correlation coefficients) were selected for multiregression models. Two classes of models were obtained: (1) linear or nonlinear MR models which were generated starting from the complete set of descriptors, and (2) nonlinear MR models which were generated starting from the same set of descriptors that was used in the NNE modeling. In addition, the descriptor selection method from CROMRsel was compared with the GFA method included in the QSAR module of the Cerius2 program. For each data set it has been found that the MR models have better cross-validated statistical parameters than the corresponding NNE models and that CROMRsel selects somewhat better MR models than the GFA method. MR models are also much simpler than NNEs, which is the important surprising fact, and, additionally, express calculated dependencies in a functional form. Moreover, MR models were shown to be better than all other models obtained by different methods on the same data sets ("old" multivariate regressions, functional-link-net models, back-propagation neural networks, genetic algorithm, and partial least squares models). This study also indicated that the robust NNE models cannot generate good models when applied on small data sets, suggesting that it is perhaps better to apply robust methods (like NNE ones) on larger data sets.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Bono Lucić, Damir Nadramija, Ivan Basic, Nenad Trinajstić. Toward generating simpler QSAR models: nonlinear multivariate regression versus several neural network ensembles and some related methods.. https://doi.org/10.1021/ci025636j

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗